What's the most attractive weight-loss stock right now? We asked Seeking Alpha analysts Edmund Ingham, Stephen Ayers and Oneil Trader for their picks. Read more here.

Novo Nordisk (NVO) said its popular diabetes drug Ozempic, also known as semaglutide, has been approved to reduce the risk of kidney disease worsening, kidney failure, and death from cardiovascular ...

Tirzepatide works by targeting multiple pathways ... not interfere with the active ingredients while providing necessary structure and consistency to the product. By maintaining a clean label ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...

With the right structure, non-physicians can successfully ... like semaglutide (brand name Ozempic) and tirzepatide (brand name Mounjaro). These FDA-approved medications have gained exponential ...

Eli Lilly said on Monday it has sued two medical spas for selling unapproved products claiming to contain tirzepatide, the main ingredient in its popular weight-loss medicine Zepbound. Lilly sues ...

Weight-loss medication like Semaglutide and Tirzepatide has seen a rise in demand, causing a boom in sales. This exploding demand has caused many to wonder if they are indeed the magical solution to ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

Ozempic, or semaglutide, is a GLP-1 agonist, meaning its molecules mimic the structure of GLP-1 ... Newer GLP-1 receptor agonists like tirzepatide, (which combines a GLP-1 mimic with the mimic ...